GT Biopharma Inc
GTBP
查看详细走势图
0.845USD
+0.040+4.97%
收盘 12/24, 13:00（美东）报价延迟15分钟
5.11M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.97%
5天
+20.71%
1月
+11.01%
6月
-74.55%
今年开始到现在
-72.30%
1年
-73.59%
查看详细走势图
TradingKey GT Biopharma Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
GT Biopharma Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名173/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价8.00。中期看，股价处于上升通道。近一个月，市场表现较强，基本面评分较高，但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
GT Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
8.000
目标均价
+1131.91%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
GT Biopharma Inc亮点
亮点风险
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
GT Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
GT Biopharma Inc简介
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
公司代码GTBP
公司GT Biopharma Inc
CEOBreen (Michael)
网址https://www.gtbiopharma.com/
常见问题
GT Biopharma Inc(GTBP)的当前股价是多少？
GT Biopharma Inc(GTBP)的当前股价是 0.845。
GT Biopharma Inc的股票代码是什么？
GT Biopharma Inc的股票代码是GTBP。
GT Biopharma Inc股票的52周最高点是多少？
GT Biopharma Inc股票的52周最高点是3.850。
GT Biopharma Inc股票的52周最低点是多少？
GT Biopharma Inc股票的52周最低点是0.540。
GT Biopharma Inc的市值是多少？
GT Biopharma Inc的市值是5.11M。
GT Biopharma Inc的净利润是多少？
GT Biopharma Inc的净利润为-13.16M。
现在GT Biopharma Inc(GTBP)的股票是买入、持有还是卖出？
根据分析师评级，GT Biopharma Inc(GTBP)的总体评级为买入，目标价格为8.000。
GT Biopharma Inc(GTBP)股票的每股收益（EPS TTM）是多少
GT Biopharma Inc(GTBP)股票的每股收益（EPS TTM）是-3.491。
相关品种
